Actavis PLC (ACT.N)

ACT.N on New York Stock Exchange

199.38USD
1:30am IST
Price Change (% chg)

$5.44 (+2.81%)
Prev Close
$193.94
Open
$197.82
Day's High
$200.47
Day's Low
$195.03
Volume
342,458
Avg. Vol
402,857
52-wk High
$230.57
52-wk Low
$96.16

ACT.N

Chart for ACT.N

About

Actavis PLC is a global, integrated specialty pharmaceutical company. The Company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company produces and markets generic, branded generic, branded and over-the-counter (OTC) pharmaceutical products covering all therapeutic classes.... (more)

Overall

Beta: 0.29
Market Cap (Mil.): $33,841.49
Shares Outstanding (Mil.): 174.49
Dividend: --
Yield (%): --

Financials

  ACT.N Industry Sector
P/E (TTM): -- 32.56 32.65
EPS (TTM): -5.43 -- --
ROI: -4.88 19.75 19.01
ROE: -11.23 20.45 19.78
Search Stocks

Sanofi sues Actavis over generic version of heart drug Multaq

PARIS, Feb 28 - French pharmaceutical company Sanofi has filed a lawsuit against Actavis over alleged patent infringements on its heart drug Multaq, hindering the generic drugmaker's plans to produce its own version of the drug.

28 Feb 2014

Bankers welcome Actavis' $7 billion syndicated loan

LONDON - U.S. bankers hungry for opportunities to lend to America's top companies are welcoming a $7 billion financing package backing generic drugmaker Actavis Plc's acquisition of Forest Laboratories.

21 Feb 2014

RLPC-US bankers welcome Actavis' $7bln syndicated loan

LONDON, Feb 20 - U.S. bankers hungry for opportunities to lend to America's top companies are welcoming a $7 billion financing package backing generic drugmaker Actavis Plc's acquisition of Forest Laboratories.

21 Feb 2014

Actavis in talks on $7 billion financing for Forest Labs buy

NEW YORK - Generic drugmaker Actavis Plc has begun discussions with its core bank group to syndicate the $7 billion financing slated to back its acquisition of Forest Laboratories Inc, sources told Thomson Reuters LPC.

20 Feb 2014

UPDATE 1-RLPC: Actavis in talks on $7B financing for Forest Labs buy

NEW YORK, Feb 19 - Generic drugmaker Actavis Plc has begun discussions with its core bank group to syndicate the $7 billion financing slated to back its acquisition of Forest Laboratories Inc, sources told Thomson Reuters LPC.

20 Feb 2014

RLPC: Actavis in talks on $6.25-6.5B financing for Forest Labs buy

NEW YORK, Feb 19 - Generic drugmaker Actavis PLC has begun discussions with its core bank group to syndicate the $6.25-6.5 billion financing slated to back its acquisition of Forest Laboratories Inc, sources told Thomson Reuters LPC.

19 Feb 2014

Icahn says Actavis-Forest deal validates shareholder activism

- After a nearly three-year campaign at Forest Laboratories Inc that spanned two proxy battles and the ousting of a chief executive, billionaire activist investor Carl Icahn has once again ended up on top.

19 Feb 2014

Icahn says Actavis-Forest deal validates shareholder activism

Feb 18 - After a nearly three-year campaign at Forest Laboratories Inc that spanned two proxy battles and the ousting of a chief executive, billionaire activist investor Carl Icahn has once again ended up on top.

19 Feb 2014

US STOCKS-S&P 500 ticks up on M&A; Nasdaq extends winning streak

* Coke shares fall after results, drag on Dow industrials

19 Feb 2014

Actavis to buy Forest for $25 billion; windfall for investor Icahn

- Generic drugmaker Actavis Plc said on Tuesday it would buy Forest Laboratories Inc for about $25 billion in cash and stock, giving it a major focus on higher-margin, branded treatments for Alzheimer's, hypertension and other disorders.

19 Feb 2014

Competitors

Earnings vs. Estimates

Search Stocks